Zackery P. Bulman
Director, Infectious Diseases Pharmacology Fellowship, Pharmacy Practice
Associate Professor, University of Illinois at Chicago
Contact
Office Phone:
Email:
Related Sites:
About
Research Interests:
The medical community is at a constant state of war with bacteria to both prevent and overcome antimicrobial resistance, which is one of the largest threats to global health. The frequency and nature of bacterial cell replication combined with the widespread use of antibiotics suggests that antimicrobial resistance is likely to persist. Dr. Bulman’s laboratory investigates novel pharmacotherapeutic approaches that aim to overcome drug resistant bacteria and improve patient outcomes.
Teaching and Supervision
Spec Project in Pharm Pract (PMPR 390), 1/13/2025 – 5/2/2025
Undergrad Resrch Pharm Pract (PMPR 380), 1/13/2025 – 5/2/2025
Applied Research Methods (PMPR 376), 1/13/2025 – 5/2/2025
Undergrad Res Exp Pharm Pract (PMPR 300), 1/13/2025 – 5/2/2025
Concentration Research (PMPR 485), 8/26/2024 – 12/6/2024
Undergrad Resrch Pharm Pract (PMPR 380), 8/26/2024 – 12/6/2024
Undergrad Res Exp Pharm Pract (PMPR 300), 8/26/2024 – 12/6/2024
PHAR 435: Pharmacokinetics (PHAR 435), 8/19/2024 – 12/6/2024
Applied Research Methods (PMPR 376), 1/8/2024 – 4/26/2024
Selected Grants
Antibiotics for K. pneumoniae targeting the essential bacterial enzyme peptide-tRNA hydrolase, Bill and Melinda Gates Foundation., 1/1/2026 - 12/31/2028, No Obligated Amount Set; Anticipated Amount: $3040616
Structural, functional, and microbiological exploration toward synergistic dual aminoglycoside combinations, National Institutes of Health (National Institute of Allergy and Infectious Diseases)., 4/11/2025 - 3/31/2027, Obligated Amount: $237518; Anticipated Amount: $434954
Innovating Gram-Negative Therapeutics (IGNITE), National Institutes of Health., 1/1/2025 - 12/31/2030, Obligated Amount: $34623584; No Anticipated Amount Set
Pharmacodynamic activity of imipenem-relebactam against Mycobacterium abscessus in time-kill assays and the hollow fiber infection model, Merck & Co Inc., 11/6/2024 - 11/5/2025, Obligated Amount: $168760.2; Anticipated Amount: $168760.2
Precise Combination Strategies Targeting Carbapenem-Resistant Klebsiella pneumoniae, National Institutes of Health (National Institute of Allergy and Infectious Diseases)., 12/5/2022 - 11/30/2027, Obligated Amount: $2233072; Anticipated Amount: $3660946
Selected Publications
Singh, Nidhi, Dangi, Bikash, Johnson, Jeremy J, Louie, Arnold, Karunanidhi, Arunkumar, Curry, Brooke N, Mitarai, Satoshi, Daley, Charles L, Hobbie, Sven N, Bulman, Zackery P. (2025). Pharmacodynamic assessment of apramycin against Mycobacterium abscessus in a hollow fibre infection model. Journal of Antimicrobial Chemotherapy, 80, (5), 1309-1314. doi:10.1093/jac/dkaf073.
Bulman, Zackery P, Cao, Lishan, Curry, Brooke N, Biagi, Mark, Vivo, Amanda, Suda, Katie J, Evans, Charlesnika T. (2024). Ceftazidime/avibactam alone or in combination with an aminoglycoside for treatment of carbapenem-resistant Enterobacterales infections: A retrospective cohort study. International Journal of Antimicrobial Agents, 64, (5), 107321. doi:10.1016/j.ijantimicag.2024.107321.
Shin, Eunjeong, Zhang, Yongzhen, Zhou, Jieqiang, Lang, Yinzhi, Sayed, Alaa RM, Werkman, Carolin, Jiao, Yuanyuan, Kumaraswamy, Monika, Bulman, Zackery P, Luna, Brian M, Bulitta, Jürgen B. (2024). Improved characterization of aminoglycoside penetration into human lung epithelial lining fluid via population pharmacokinetics. Antimicrobial Agents and Chemotherapy, 68, (2), e01393-e01323. doi:10.1128/aac.01393-23.
Andrianopoulou, Angeliki, Sokolowski, Karol, Wenzler, Eric, Bulman, Zackery P, Gemeinhart, Richard A. (2024). Assessment of antibiotic release and antibacterial efficacy from pendant glutathione hydrogels using ex vivo porcine skin. Journal of Controlled Release, 365, 936-949. doi:10.1016/j.jconrel.2023.12.008.
Palmer, Mary E, Belcher, Rachel M, Engeleit, Anastasia, Wenzler, Eric, Bulman, Zackery P, Benken, Scott T. (2023). Pharmacokinetics and dialytic clearance of baricitinib during in vivo continuous venovenous haemodialysis in a patient with COVID-19. International Journal of Antimicrobial Agents, 62, (3), 106920. doi:10.1016/j.ijantimicag.2023.106920.
Bulman, Zackery P, Wicha, Sebastian G, Nielsen, Elisabet I, Lenhard, Justin R, Nation, Roger L, Theuretzbacher, Ursula, Derendorf, Hartmut, Tängdén, Thomas, Zeitlinger, Markus, Landersdorfer, Cornelia B, Bulitta, Jürgen B, Friberg, Lena E, Li, Jian, Tsuji, Brian T, Pharmacology, International Society of Anti-Infective, Group, European Society of Clinical Microbiology and Infectious Diseases Pharmacokinetics and Pharmacodynamics of Anti-Infectives Study, Group, International Society of Antimicrobial Chemotherapy Anti-Infective Pharmacology Working. (2022). Research priorities towards precision antibiotic therapy to improve patient care. The Lancet Microbe, 3, (10), e795-e802. doi:10.1016/s2666-5247(22)00121-5.
Smith, Nicholas M, Boissonneault, Katie Rose, Chen, Liang, Petraitis, Vidmantas, Petraitiene, Ruta, Tao, Xun, Zhou, Jieqiang, Lang, Yinzhi, Kavaliauskas, Povilas, Bulman, Zackery P, Holden, Patricia N, Cha, Raymond, Bulitta, Jürgen B, Kreiswirth, Barry N, Walsh, Thomas J, Tsuji, Brian T. (2022). Mechanistic Insights to Combating NDM- and CTX-M-Coproducing Klebsiella pneumoniae by Targeting Cell Wall Synthesis and Outer Membrane Integrity. Antimicrobial Agents and Chemotherapy, 66, (9), e00527-e00522. doi:10.1128/aac.00527-22.
Singh, Nidhi, Poggensee, Linda, Huang, Yanqin, Evans, Charlesnika T, Suda, Katie J, Bulman, Zackery P. (2022). Antibiotic susceptibility patterns of viridans group streptococci isolates in the United States from 2010 to 2020. JAC-Antimicrobial Resistance, 4, (3), dlac049. doi:10.1093/jacamr/dlac049.
Huang, Yanqin, Rana, Amisha P, Wenzler, Eric, Ozer, Egon A, Krapp, Fiorella, Bulitta, Jürgen B, Hauser, Alan R, Bulman, Zackery P. (2022). Aminoglycoside-resistance gene signatures are predictive of aminoglycoside MICs for carbapenem-resistant Klebsiella pneumoniae. Journal of Antimicrobial Chemotherapy, 77, (2), 356-363. doi:10.1093/jac/dkab381.
Professional Leadership
AST Breakpoints Working Group Member, Clinical and Laboratory Standards Institute, 1/1/2025 - Present
SIDP Website Committee, Society for Infectious Diseases Pharmacists, 11/1/2023 - 10/31/2024
SIDP Website Committee, Society for Infectious Diseases Pharmacists, 11/1/2022 - 10/31/2023
ISAC Anti-Infective Pharmacology Working Group, 12/2/2019 - Present
ISAP Treasurer, International Society of Anti-Infective Pharmacology, 2018 - Present
Notable Honors
2024, Investigator of the Year Award, University of Illinois Chicago Retzky College of Pharmacy
2023, New Investigator Award, American College of Clinical Pharmacy
2023, Early Career Investigator Award, Society of Infectious Diseases Pharmacists (SIDP)
2023, UIC Researcher of the Year- Rising Star Award in Clinical Sciences, University of Illinois at Chicago
2020, FISAC, International Society of Antimicrobial Chemotherapy
2020, Hans W. Vahlteich Research Scholar,
Education
Degrees:
PharmD, University at Buffalo, State University of New York, United States, 2015
B.S., Rochester Institute of Technology, United States, 2011
Postgraduate Training:
Infectious Diseases Pharmacology Fellowship, University at Buffalo, State University of New York, United States, 2017
Clinical and Translational Research Fellow, VA Western New York Healthcare System, United States, 2017